Journal article
SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
Abstract
BACKGROUND: Randomized clinical trials (RCTs) of interventions for the hepatitis C virus have historically used sustained virological response (SVR) at 24 weeks after treatment (SVR24) as the key effect measure. However, recent RCTs investigating the efficacy of new direct acting agents (DAAs) have used SVR at 12 weeks after treatment (SVR12). While there is evidence to suggest SVR24 and SVR12 are similar in patients receiving new DAAs, this is …
Authors
Thorlund K; Druyts E; Mills EJ
Journal
Clinical Epidemiology, Vol. 6, No. 0, pp. 49–58
Publisher
Taylor & Francis
Publication Date
January 15, 2014
DOI
10.2147/clep.s53302
ISSN
1179-1349